Skip to main content
EJNMMI Research

Table 2 SUVmax values of patients with CYP3A4 inhibitors during the [68 Ga]Ga-DOTA-TATE PET/CT compared to patients without CYP3A4 inhibitor use

From: CYP3A4 inhibitors do not influence [68Ga]Ga-DOTA-TATE uptake in liver tissue

Characteristic

No CYP3A4*

CYP3A4*

p value†

SUVmax TBR‡

26.6, 18.6–34.1

n = 43

28.1, 16.3–60.0

n = 10

0.838

SUVmax LBR

8.9, 7.2–11.9

n = 50

9.2, 7.0–14.1

n = 20

0.550

SUVmax TLR‡

3.0, 1.8–4.7

n = 43

3.4, 1.7–5.7

n = 10

0.733

  1. *Mean ± standard deviation (median, interquartile range)
  2. †Mann–Whitney U test
  3. ‡Some patients did not have a diagnosed tumour or had already undergone surgical resection of the primary tumour
  4. TBR tumour-to-background ratio, LBR liver-to-background ratio, TLR tumour-to-liver ratio
Back to article page